|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2011-5-18
|
|
pubmed:abstractText |
The aim of this analysis is to investigate the mean incremental costs and life expectancy associated with two first-line treatments for advanced non-squamous non-small cell lung cancer (NSCLC) in Korea and Taiwan; bevacizumab plus cisplatin and gemcitabine (BevCG) and cisplatin plus pemetrexed (CP).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1743-7563
|
|
pubmed:author |
pubmed-author:AhnMyung-JuMJ,
pubmed-author:BaeEun-JinEJ,
pubmed-author:ChangJohn Wen-ChengJW,
pubmed-author:HsiaTe-ChunTC,
pubmed-author:KangJin HyoungJH,
pubmed-author:KangMijeongM,
pubmed-author:KimHeung TaeHT,
pubmed-author:KimJoo-HangJH,
pubmed-author:KimSang-WeSW,
pubmed-author:ListerJohannaJ,
pubmed-author:TsaiChun-MingCM,
pubmed-author:WalzerStefanS,
pubmed-author:WrightElaineE
|
|
pubmed:copyrightInfo |
© 2011 Blackwell Publishing Asia Pty Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
7 Suppl 2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
22-33
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21585705-Adult,
pubmed-meshheading:21585705-Aged,
pubmed-meshheading:21585705-Antibodies, Monoclonal,
pubmed-meshheading:21585705-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21585705-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21585705-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:21585705-Cisplatin,
pubmed-meshheading:21585705-Cost-Benefit Analysis,
pubmed-meshheading:21585705-Disease-Free Survival,
pubmed-meshheading:21585705-Female,
pubmed-meshheading:21585705-Glutamates,
pubmed-meshheading:21585705-Guanine,
pubmed-meshheading:21585705-Humans,
pubmed-meshheading:21585705-Korea,
pubmed-meshheading:21585705-Lung Neoplasms,
pubmed-meshheading:21585705-Male,
pubmed-meshheading:21585705-Middle Aged,
pubmed-meshheading:21585705-Survival Analysis,
pubmed-meshheading:21585705-Taiwan
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
|
|
pubmed:affiliation |
Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. silkahn@skku.edu
|
|
pubmed:publicationType |
Journal Article
|
